Literature DB >> 18667022

Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function.

Hisashi Hashimoto1, Atsumi Kojima, Tamotsu Sudo, Noriyoshi Ohki, Satoshi Yamaguchi, Yoshiki Mikami, Masaharu Ito, Ryuichiro Nishimura.   

Abstract

Uterine papillary serous carcinoma is an uncommon histologic subtype of endometrial cancer that behaves aggressively and has a poor prognosis. We successfully established a uterine papillary serous carcinoma cell line. The population-doubling time was approximately 16 h. Although loss of p53 function is considered critical for the molecular pathogenesis of uterine papillary serous carcinoma, p53 was not only mutated but functionally active in this cell line. This newly established cell line should be useful for investigating the characteristics of uterine papillary serous carcinoma.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18667022     DOI： 10.1111/j.1749-0774.2008.00051.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN： 0914-7470            Impact factor:   4.174


  13 in total

1.  The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.

Authors:  S F Lax; B Kendall; H Tashiro; R J Slebos; L Hedrick
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

Review 2.  The p53-Mdm2 module and the ubiquitin system.

Authors:  Dan Michael; Moshe Oren
Journal:  Semin Cancer Biol       Date:  2003-02       Impact factor: 15.707

3.  Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features.

Authors:  M E Sherman; P Bitterman; N B Rosenshein; G Delgado; R J Kurman
Journal:  Am J Surg Pathol       Date:  1992-06       Impact factor: 6.394

4.  Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.

Authors:  P Lim; A Al Kushi; B Gilks; F Wong; C Aquino-Parsons
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

5.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

6.  p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.

Authors:  H Tashiro; C Isacson; R Levine; R J Kurman; K R Cho; L Hedrick
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

7.  Uterine papillary serous carcinoma. A clinical study.

Authors:  G Gitsch; M L Friedlander; G V Wain; N F Hacker
Journal:  Cancer       Date:  1995-05-01       Impact factor: 6.860

8.  The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies.

Authors:  I Persson
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1985

9.  Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.

Authors:  B Nordström; P Strang; A Lindgren; R Bergström; B Tribukait
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

10.  Loss of p53 function in uterine papillary serous carcinoma.

Authors:  S Kovalev; N D Marchenko; B G Gugliotta; E Chalas; J Chumas; U M Moll
Journal:  Hum Pathol       Date:  1998-06       Impact factor: 3.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.